Sm-TSP-2/Alhydrogel/GLA-AF

Phase 1Biologic

NNational Institute of Allergy and Infectious Diseases (NIAID)

Sm-TSP-2/Alhydrogel/GLA-AF is one of 5 biologic programs targeting Intestinal Schistosomiasis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal SchistosomiasisActive, not recruiting

Intestinal SchistosomiasisPhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Intestinal Schistosomiasis

#DrugCompanyPhaseTrials

Biltricide

Bayer

Approved

—2

Hepatitis B Virus Vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 3

Sm-Tsp-2/alhydrogel

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

2 4

Sm-TSP-2/Alhydrogel/GLA-AF

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 5

GLA-AF

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intestinal Schistosomiasis1 trial

A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02337855·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sm-TSP-2/Alhydrogel/GLA-AF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sm-TSP-2/Alhydrogel/GLA-AF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sm-TSP-2/Alhydrogel/GLA-AF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Sm-TSP-2/Alhydrogel/GLA-AF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intestinal Schistosomiasis1 trial

References

Drug Info

Quick Facts

Related News